期刊
PRIMARY CARE
卷 43, 期 4, 页码 677-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.pop.2016.07.002
关键词
MGUS; Multiple myeloma; Waldenstrom macroglobulinemia; Amyloidosis; POEMS
资金
- Abbvie
- Gilead
- Millennium
- Pharmacyclics
Plasma cell disorders are benign, premalignant, and malignant conditions characterized by the presence of a monoclonal paraprotein detected in serum or urine. These conditions are biologically, pathologically, and clinically heterogeneous. There have been major advances in the understanding of the biology of these diseases, which are promoting the development of therapies with novel mechanisms of action. Novel agents such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have gained approval in the United States and Europe for the treatment of plasma cell disorders. Such therapies are translating into higher rates of response and survival and better toxicity profiles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据